Free Trial

Novartis (NVS) Stock Forecast & Price Target

Novartis logo
$112.23 +1.06 (+0.95%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$106.62 -5.62 (-5.00%)
As of 04/25/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
6
Buy
2

Based on 11 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 3 have given a sell rating, 6 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for NVS.

Consensus Price Target

$123.38
9.93% Upside
According to the 11 analysts' twelve-month price targets for Novartis, the average price target is $123.38. The highest price target for NVS is $130.00, while the lowest price target for NVS is $120.00. The average price target represents a forecasted upside of 9.93% from the current price of $112.23.
Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

Sign Up

NVS Analyst Ratings Over Time

TypeCurrent Forecast
4/26/24 to 4/26/25
1 Month Ago
3/27/24 to 3/27/25
3 Months Ago
1/27/24 to 1/26/25
1 Year Ago
4/27/23 to 4/26/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$123.38$123.38$123.38$115.00
Forecasted Upside9.93% Upside10.69% Upside23.47% Upside18.02% Upside
Consensus Rating
Hold
Reduce
Reduce
Hold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside9.93% Upside2,806.54% Upside21.41% Upside
News Sentiment Rating
Positive News

See Recent NVS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2025BNP Paribas
3 of 5 stars
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/13/2025UBS Group
3 of 5 stars
Matthew Weston
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
2/12/2025Morgan Stanley
3 of 5 stars
 Initiated CoverageUnderweight
2/4/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
2/3/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweight ➝ Underweight
12/4/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Reduce
11/19/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
10/30/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$118.00 ➝ $120.00+8.53%
9/11/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$135.00 ➝ $130.00+11.08%
9/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Quigley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$119.00 ➝ $121.00+1.37%
9/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:27 AM ET.


Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 24, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novartis AG:

  • The current stock price is around $111.52, reflecting a stable performance in the market.
  • Recent upgrades from multiple analysts, including a "strong-buy" rating from BNP Paribas, indicate positive sentiment and potential for growth.
  • Institutional investors own approximately 13.12% of the company's stock, suggesting confidence from large financial entities.
  • Novartis AG has a solid market capitalization of $226.26 billion, which positions it as a significant player in the pharmaceutical industry.
  • The company has demonstrated resilience with a low debt-to-equity ratio of 0.48, indicating a strong balance sheet and financial stability.

Novartis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novartis AG for these reasons:

  • Despite recent upgrades, there are still three analysts who have rated the stock with a sell rating, indicating some skepticism about its future performance.
  • The stock has a price-to-earnings ratio of 18.83, which may be considered high compared to industry averages, potentially limiting upside for new investors.
  • Recent trading volumes have shown fluctuations, with volumes sometimes falling below average, which could indicate reduced investor interest.
  • Market analysts have mixed opinions, with some maintaining a "hold" rating, suggesting uncertainty about the stock's short-term prospects.
  • Novartis AG's current ratio of 1.04 is just above the threshold of 1, which may raise concerns about its ability to cover short-term liabilities effectively.

NVS Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $123.38, with a high forecast of $130.00 and a low forecast of $120.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 3 sell ratings, 6 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted upside of 9.93% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 2 upgrades by analysts.

Novartis has been rated by research analysts at Barclays, BNP Paribas, Deutsche Bank Aktiengesellschaft, Morgan Stanley, and UBS Group in the past 90 days.

Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.


This page (NYSE:NVS) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners